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Background: Environmental factors can influence obesity by epigenetic mechanisms. Adipose tissue plays a key
role in obesity-related metabolic dysfunction, and gastric bypass provides a model to investigate obesity and
weight loss in humans.
Results: Here, we investigate DNA methylation in adipose tissue from obese women before and after gastric
bypass and significant weight loss. In total, 485,577 CpG sites were profiled in matched, before and after weight
loss, subcutaneous and omental adipose tissue. A paired analysis revealed significant differential methylation in
omental and subcutaneous adipose tissue. A greater proportion of CpGs are hypermethylated before weight loss
and increased methylation is observed in the 3′ untranslated region and gene bodies relative to promoter regions.
Differential methylation is found within genes associated with obesity, epigenetic regulation and development,
such as CETP, FOXP2, HDAC4, DNMT3B, KCNQ1 and HOX clusters. We identify robust correlations between changes in
methylation and clinical trait, including associations between fasting glucose and HDAC4, SLC37A3 and DENND1C in
subcutaneous adipose. Genes investigated with differential promoter methylation all show significantly different
levels of mRNA before and after gastric bypass.
Conclusions: This is the first study reporting global DNA methylation profiling of adipose tissue before and after
gastric bypass and associated weight loss. It provides a strong basis for future work and offers additional evidence
for the role of DNA methylation of adipose tissue in obesity.Background
Obesity is a major public health problem and a risk factor
for type-2 diabetes, hypertension and cardiovascular disease
[1-4]. Adipose tissue is an endocrine organ [5] and plays a
fundamental role in obesity-related metabolic dysfunction
[6]. Different adipose tissue depots within the body have
distinct structural and biochemical properties [7,8]. In
humans, these depots can broadly be divided into two
categories, subcutaneous and intra-abdominal. Metabolic
risk is affected by both the distribution of body fat between
different adipose tissue depots within an individual and the* Correspondence: Donia.Macartney@esr.cri.nz
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unless otherwise stated.differing natures of the depots themselves [9-11]. Increased
intra-abdominal adipose tissue has been correlated with
an increased risk of obesity-related co-morbidities such
as cardiovascular disease, atherosclerosis and type-2
diabetes [12-14].
Causal genetic variants of obesity and type-2 diabetes
have been identified through candidate gene, family-based
linkage and large scale association analyses. However,
apart from the small number of rare monogenic disease
variants application of genetics to clinical management
has not occurred. Reasons for this include the relatively
small effect size of common genetic variants, the location
of a large number of disease associated loci in intergenic
regions of the genome, and the likelihood that additional
causal variants are yet to be identified [15,16].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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role in complex disease, and provides mechanisms
whereby environmental factors can influence complex
diseases such as obesity and type-2 diabetes [17,18].
Thus, epigenetics may explain some of the ‘missing
heritability’ of complex disease, and, because of effects
on regulation, provide a functional role for some of the
intergenic loci associated with disease.
Animal and human studies have shown that the DNA
methylation status of genes in offspring can be altered
in utero by the maternal dietary environment [19-23].
Godfrey et al. [24] further reported that the child’s
methylation status correlated with adiposity in later life.
Feinberg et al. [25] identified four variably methylated
regions in lymphocytes which correlated with body
mass index (BMI); these regions were located in or near
genes previously implicated in body weight regulation or
diabetes. Obesity has also been associated with genome-
wide DNA methylation changes in peripheral blood
[26-28], and methylation differences have been reported
in peripheral blood in response to caloric restriction [29]
and weight loss intervention [30]. In addition, a recent
genome-wide analysis of peripheral blood revealed type-2
diabetes related DNA methylation variations [31], and an-
other investigated associations between methylation and
fasting glucose, insulin and insulin resistance [32].
Epigenetic signatures are acquired by cells during deve-
lopment and differentiation. DNA methylation changes,
such as demethylation of specific sequences within the
leptin and GLUT4 gene promoters is observed during
adipogenesis [33,34] and adipose tissue precursor cells
retain their DNA methylation profile through generations
of culture [35]. In addition, women with a lower baseline
methylation of the leptin and TNF-alpha gene promoters
in subcutaneous adipose tissue responded better to dietary
intervention [36].
A small number of studies have reported DNA
methylation profiling of human subcutaneous adipose
tissue. The first, by Bouchard et al. [37] assayed 15 K
CpG dinucleotides (CpGs) in subcutaneous adipose tis-
sue from high (3% to 6% loss of body fat) and low (≤3%
loss of body fat) responders to caloric restriction
reporting DNA methylation differences between the
two groups at 35 loci before weight loss and 3 loci after
weight loss. More recently a couple of studies have in-
vestigated DNA methylation differences between twins
[38,39] and another compared thigh subcutaneous adi-
pose before and after exercise intervention [40]. Investi-
gation of the omentum DNA methylome has been
reported in the context of both an identification of
tissue-specific differentially methylation using the Illu-
mina 450 K platform [41], and a comparison of global
methylation patterns with subcutaneous adipose using a
luminometric assay [42].Given this increasing evidence for the involvement of
epigenetics in complex disease and obesity in particular
[17,18], together with the role that adipose tissue plays
in disease progression, we hypothesised that epigenetic
changes would be present in this tissue in the context of
obesity and weight loss. Roux en Y gastric bypass surgery
(from now on referred to as gastric bypass) is used to
treat morbid obesity and results in marked weight loss
[43,44]. Therefore, we use gastric bypass as a model for
significant weight loss. Two studies have investigated
global DNA methylation before and after gastric bypass,
one in skeletal muscle and the other in liver [45,46].
Here we extend this to two adipose tissue depots and
present the first high density DNA methylation profile of
subcutaneous abdominal and intra-abdominal omental
adipose tissue before and after gastric bypass and weight
loss.
Results
Differential methylation of adipose tissue before and
after weight loss
Global differential methylation
DNA methylation was analysed independently in subcuta-
neous abdominal adipose and intra-abdominal omental
adipose (referred to as subcutaneous adipose and omen-
tum, respectively, from this point) before and after gastric
bypass and weight loss in 15 women (clinical and an-
thropometric data presented in Table 1). We investigated
global DNA methylation (450,315 CpG sites passing qual-
ity filtering) and plotted this at the level of genomic gene
annotation (Figure 1). This revealed a clear pattern of
methylation across the genome with least methylation in
promoter regions and greatest methylation in the 3′ UTRs
(untranslated regions) and gene bodies. While the overall
pattern was the same in both adipose tissues, significantly
more methylation was observed before than after weight
loss for all gene regions in subcutaneous adipose and all
except TSS200, 5′UTR and the first exon in omentum
(Figure 1). In order to investigate if the global pattern of
methylation across gene regions was similar in other tis-
sues we investigated publically available data from 15
different tissues (including two samples from healthy
normal adipose). We observed a very similar pattern of
global DNA methylation across all tissue samples
analysed (Additional file 1).
Differential methylation of individual CpG loci
We compared the methylation (beta value) of individual
CpG sites before and after weight loss. Initial analysis
using a relaxed multiple testing threshold (P < 1 × 10−5)
to interrogate the data revealed 1,347 and 25,729 differ-
entially methylated loci for omentum and subcutaneous
adipose, respectively. Unsupervised hierarchical cluster-
ing grouped the samples principally by sampling time
Table 1 Clinical and anthropometric data for individuals in the study
Trait Before weight loss After weight loss T statistic P value
Age (years) 44 (+/− 10) 45 (+/− 10) −7.64 1.16 × 10−6
Weight (kg) 123.9 (+/− 33.32) 76.2 (+/− 15.4) 8.31 4.42 × 10−7
BMI (kg/m2) 47.6 (+/− 11.3) 29.3 (+/− 5.5) 9.10 1.48 × 10−7
Glucose (mmol/L) 5.5 (+/− 1.2) 4.6 (+/− 0.6) 2.35 0.017
Insulin (pmol/L) 176.2 (+/− 168.1) 33.4 (+/− 19.3) 3.04 0.006
HbA1c 6.0 (+/− 0.6) 5.5 (+/− 0.5) 2.42 0.018
Triglycerides (mmol/L) 1.6 (+/− 0.7) 1.0 (+/− 0.3) 3.00 0.005
Total cholesterol (mmol/L) 5.3 (+/− 0.8) 4.6 (+/− 0.6) 4.23 4.48 × 10−4
HDL (mmol/L) 1.4 (+/− 0.4) 1.8 (+/− 0.9) −1.46 0.083
LDL (mmol/L) 3.2 (+/− 1.1) 2.6 (+/− 0.6) 2.71 0.009
Systolic blood pressure (mmHg) 135 (+/− 18) 115 (+/− 9) 3.37 0.003
Diastolic blood pressure (mmHg) 78 (+/− 13) 73 (+/− 9) 1.67 0.061
Time (months) 17.6 (+/− 6.9)
Data are expressed as means +/− standard deviation, based on a paired t-test and one-tailed P value (given that gastric bypass is known to result in a marked
reduction in weight and metabolic risk).
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[47] correction was applied (P <1 × 10−7) 15 and 3,601
differentially methylated CpG sites were observed in
omentum and subcutaneous adipose (Additional file 2),
respectively.
Differentially methylated CpG sites were present across
the genome with all chromosomes represented. Figure 3
presents a genome-wide differential methylation plot
(Δbeta) for CpG sites passing Bonferroni correction inFigure 1 Global DNA methylation in human adipose tissue plotted by
annotation. Data are presented as mean +/− standard deviation. *Significan
weight loss, Bonferroni adjusted P <0.05. TSS proximal promoter defined as
start site. UTR: untranslated region. Ab – subcutaneous adipose, Om – omesubcutaneous adipose and Table 2 provides summary
statistics for both tissues. The top 20 most hyper and
hypo methylated CpG sites in subcutaneous adipose
mapping to known genes are shown in Table 3 (full
dataset, Additional file 2), and the 15 differentially
methylated CpG sites passing Bonferroni correction in
omentum are presented in Table 4.
When we looked for an overlap between the 15 and
3,601 robustly identified CpG sites in omentum andgene region. Gene regions are based on Illumina 450 K beadchip
t difference between average DNA methylation before and after
200 bp (TSS200) or 1,500 bp (TSS1500) upstream of the transcription
ntum before (pre) and after (post) gastric bypass and weight-loss.
Figure 2 Heatmap of hierarchical clustering for differentially methylated CpG sites in omentum (A) and subcutaneous adipose (B).
CpG sites passing a relaxed (P <1 × 10−5) are represented. Dark blue to white indicates hypermethylation through hypomethylation. OP1 and OP2
indicate samples taken before and after gastric bypass, respectively; numeral indicates samples from individuals 1 to 15.
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Figure 3 Genome-wide differential methylation in subcutaneous
adipose. Difference in methylation (Δbeta) for all CpG sites passing
Bonferroni correction is plotted. Δbeta is weighted by t-statistic such
that distance from central core (grey) indicates increasing levels of
statistical significance. Red dots represent CpG sites hypermethylated
and blue dots CpG sites hypomethylated, respectively, before weight
loss. Chromosomes are shown clockwise from 1 through X.
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mina probe cg08514779), located in an intergenic region
on chromosome 13 (Δbeta 0.12 subcutaneous adipose,
Δbeta 0.07 omentum). Two other genes, PDE7B and
SLC9A3, had differentially methylated sites in both tissues
but not at the same CpG loci.
Next we looked at the number of genes which had
multiple differentially methylated CpG sites. Of the
3,601 CpG sites in subcutaneous adipose (corresponding
to 1,889 unique genes) 438 genes had >1 and 15 genes
had ≥6. Of these 12/15 showed consistent hypermethyla-
tion of all CpG sites before weight loss (GNG7 9 CpGs
Δbeta 0.04-0.20, C7orf50 8 CpGs Δbeta 0.08-0.19,
PRDM16 8 CpGs Δbeta 0.07-0.16, TRIM2 7 CpGs Δbeta
0.12-0.19, COL11A2 7 CpG sites Δbeta 0.07-0.15, FOXP2
6 CpGs Δbeta 0.09-0.20, FRMD4A, 6 CpG sites Δbeta
0.10-0.17, GPR37L1 6 CpGs Δbeta 0.14-0.27, KCNQ1 6
CpGs Δbeta 0.06-0.10, RASA3 6 CpGs Δbeta 0.07-0.15,
THBS1 6 CpGs Δbeta 0.12-0.20, TNXB 6 CpGs Δbeta
0.05-0.15). Three genes showed hypomethylation of oneTable 2 Summary of differentially methylated CpG sites whic
Tissue Number of
CpG sites
CpG sites mapping
to known genes
(unique)
CpG sites mapping
to intergenic
regions
M
b
lo
Omentum 15 11 (11) 4 1
Subcutaneous
adipose
3,601 2,458 (1,889) 1,143 3CpG before weight loss and hypermethylation of the
remaining CpGs (PRKCZ 8/9 CpG Δbeta 0.08-0.16, 1/9
Δbeta −0.10, PTPRN2 7/8 CpGs Δbeta 0.07-0.17, 1/8
Δbeta −0.11, SHANK2 5/6 CpG Δbeta 0.9-0.10, 1/6
Δbeta −0.16). Further information regarding these sites
can be found highlighted within Additional file 2.
To further investigate genomic regions with consist-
ent, extended differential methylation we used the probe
lasso approach as implemented in ChAMP [48]. This
analysis was performed on probes passing a more re-
laxed adjusted P value, Benjamini-Hochberg rather than
Bonferroni, in order to increase the number of sites for
DMR (differentially methylated region) identification.
Analysis of subcutaneous adipose revealed 195 DMRs
passing a nominal P <0.05. These DMRs mapped to 162
annotated loci (Additional file 3), including five with two
DMRs (TNXB, PRKCZ, IQCE, LRRC17/FBXL13, HOXC4).
Of the 15 genes in which we observed ≥6 probes passing
Bonferroni correction DMRs were identified in eight,
which reflects the method of DMR detection implemented
in the ChAMP probe lasso protocol (in particular the size
of the lasso and P value of the individual sites). Equivalent
probe lasso analysis of the omental adipose data did not
reveal any DMRs.
Given that adipose tissue is by its nature a mixture of
cells, and that inflammation is known to play an important
role in obesity, we hypothesised that some differentially
methylated loci might correspond to epigenetic signatures
within inflammatory cells. We therefore compared the
DMRs in our subcutaneous tissue samples, with the same
regions in publicly available whole blood (as a proxy for
inflammatory cells) and publicly available healthy subcuta-
neous adipose tissue. Figure 4 presents data for a DMR
where the methylation profile of the preoperative (more
obese) tissue is higher than those for postoperative and
healthy tissue, and is thus potentially ‘pulled’ towards the
whole blood profile by its complement of inflammatory cells.
Differential methylation of genes associated with obesity,
type-2 diabetes and related traits
To investigate the potential biological significance of our
findings we interrogated the genes to which differentially
methylated CpGs mapped against the catalogue of pub-
lished Genome-wide association studies (GWAS) [49],
and identified loci associated with obesity and related
metabolic traits for 120 genes in subcutaneous adiposeh passed Bonferroni correction
ore methylated
efore weight
ss
More methylated
after weight loss
Absolute
range Δbeta
Number of CpG
sites with Δbeta
> 10% (20%)
4 1 0.034-0.112 1 (0)
,281 320 0.020-0.273 2,401 (145)
Table 3 Top20 CpG sites in known genes which were most hypermethylated or hypomethylated in subcutaneous
adipose
Ilumina probe ID Gene symbol Chromosome and map position (build 37) Δbeta T statistic P value
cg10838410 IFFO1 12: 6659524 −0.223 −10.2 6.8 × 10−8
cg27631256 TNFSF8 9: 117692745 −0.203 −11.6 1.5 × 10−8
cg21011616 HOXD4 2: 177015992 −0.188 −10.9 3.0 × 10−8
cg22491058 C4BPA 1: 207277466 −0.182 −11.4 1.8 × 10−8
cg07787634 KMO 1: 241715378 −0.177 −10.3 6.7 × 10−8
cg07420362 TRPC2 11: 3647419 −0.176 −10.5 5.1 × 10−8
cg14012082 EPX 17: 56274407 −0.176 −11.9 1.0 × 10−8
cg17518550 C1orf150 1: 247712383 −0.175 −10.3 6.3 × 10−8
cg13053653 HOXD3 2: 177037631 −0.175 −11.0 2.8 × 10−8
cg08400424 ARHGAP26 5: 142357042 −0.172 −10.2 7.7 × 10−8
cg11236746 GLB1 3:33096255 −0.172 −10.5 5.4 × 10−8
cg09359351 HSPBAP1 3:122509111 −0.171 −10.1 8.1 × 10−8
cg14118850 HPCAL1 2:10447890 −0.171 −14.5 7.9 × 10−10
cg20426866 TACC2 10:123923881 −0.170 −12.1 8.6 × 10−9
cg08055663 KCTD5 16:2737356 −0.169 −10.0 9.5 × 10−8
cg08949974 RBM47 4:40632860 −0.167 −10.0 9.0 × 10−8
cg02794695 SLA; TG 8:134072611 −0.166 −10.0 9.2 × 10−8
cg11967765 GNA12 7:2774195 −0.165 −10.0 9.7 × 10−8
cg13453168 PTPRE 10:129845660 −0.165 −11.8 1.2 × 10−8
cg26933869 ALDH4A1 1:1921807 −0.164 −10.0 9.3 × 10−8
cg10111816 CDR2 16: 22384715 0.273 12.1 8.3 × 10−9
cg07852840 SPSB4 3: 140813919 0.273 11.0 2.8 × 10−8
cg17219660 GPR37L1 1: 202091880 0.269 10.7 3.9 × 10−8
cg08344351 CMIP 16: 81507328 0.269 10.0 8.8 × 10−8
cg23753807 ABR 17: 1090291 0.265 13.7 1.7 × 10−9
cg04546573 GULP1 2: 1090291 0.263 10.4 5.8 × 10−8
cg08264805 RUSC1, C1orf104 1: 155291224 0.254 13.8 1.5 × 10−9
cg17691545 SLC10A6 4: 87770586 0.254 11.6 1.4 × 19−8
cg00838040 ATP2C2 16: 84446919 0.244 11.3 2.1 × 10−8
cg13052101 MTL5 11: 68517529 0.239 11.4 1.7 × 10−8
cg10249224 TSSK3; LOC100128071 1: 32828191 0.238 11.3 2.1 × 10−8
cg09869811 NUTF2 16:67897346 0.237 13.4 2.3 × 10−9
cg14563485 ZFP14 19:36860285 0.236 11.5 1.7 × 10−8
cg02363593 DOCK2 5:169123192 0.236 11.8 1.2 × 10−8
cg18573082 PDE7B 6:136425179 0.236 12.4 6.0 × 10−9
cg15174117 CORO2B 15:68913662 0.235 11.8 1.1 × 10−8
cg05939149 PLEKHH2 2:43986106 0.235 10.6 4.4 × 10−8
cg27083087 VGLL4 3:11610239 0.234 10.6 4.4 × 10−8
cg07080653 LNX1 4:54374249 0.233 11.7 1.2 × 10−8
cg17080882 TGFBR3 1:82191625 0.232 10.6 4.8 × 10−8
A positive value for Δbeta indicates hypermethylation before weight loss in comparison to after weight loss, and a negative value indicates hypomethylation.
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Table 4 Differentially methylated CpG sites in omentum
Ilumina probe ID Gene symbol Chromosome and map position (build 37) Δbeta T statistic P value
cg04627183 PDE7B 6: 136365249 0.070 13.5 2.0 × 10−9
cg08351331 LBP 20: 36975083 0.058 12.1 8.5 × 10−9
cg08514779 - 13: 112076555 0.073 11.9 1.1 × 10−8
cg16546882 - 7: 54731606 0.037 10.8 3.7 × 10−8
cg01907005 PLIN4 19: 4517804 0.043 10.5 5.0 × 10−8
cg00031105 RXRB 6: 33166117 0.069 10.5 5.2 × 10−8
cg06673130 CPLX1 4:778924 −0.072 −10.5 5.2 × 10−8
cg18736186 GALK2 15: 49462118 0.054 10.4 5.6 × 10−8
cg19758873 - 4: 49462118 0.059 10.2 7.6 × 10−8
cg06579248 MYO1C 17: 1375968 0.034 10.1 8.0 × 10−8
cg26790198 CSTL1 20: 23419120 0.041 10.1 8.7 × 10−8
cg15420634 SLC9A3 5: 485359 0.041 10.1 8.8 × 10−8
cg01127300 - 22: 38614796 0.112 10.0 9.3 × 10−8
cg04344695 CA12 15: 63658391 0.091 10.0 9.7 × 10−8
cg12157387 PARD3B 2: 206347777 0.083 10.0 9.7 × 10−8
All CpG sites passing Bonferroni correction are shown. A positive value for Δbeta indicates hypermethylation before weight loss in comparison to after weight
loss, and a negative value indicates hypomethylation. Gene symbol ‘-’ represents an intergenic region to which no known genes map.
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to obesity and related metabolic traits in the GWAS
catalogue (PROX1, PHACTR1, SLC22A8, SMAD3, LCAT,
DNM2). Further refining our search we investigated obes-
ity and type-2 diabetes candidates listed by McCarthy [15].
Of 57 obesity and 60 type-2 diabetes loci all but one were
present on the Illumina 450 K platform. We saw differen-
tial methylation within 9/57 obesity (single CpG sitesFigure 4 An example DMR upstream of miR-199A1. Location and orien
the miRNA are shown above. The bottom panel shows average beta value
grey dotted), subcutaneous adipose before weight loss (blue), subcutaneou
(black dotted).within: LEPR, STAB1, ZNF608, HMGA1, MSRA, TUB,
NRXN3, FTO, MC4R) and 10/59 type-2 diabetes (single
CpG sites: PROX1, RBMS1, IRS1, TCF7L2, FTO, LMNB2,
INSR. Two CpG sites within AKT2, BCL11A. Six CpG
sites within KCNQ1) genes in subcutaneous adipose. A
DMR was identified in one of the type-2 diabetes genes
(PROX1) and differential methylation of the six CpG sites
in KCNQ1 were validated by pyrosequencing (see later).tation of miR-199A1 within DMN2, as well as CpG sites upstream of
s across the DMR on chromosome 19 for: healthy whole blood (light
s adipose after weight loss (green), and healthy subcutaneous adipose
Table 5 Overlap between differentially methylated loci in subcutaneous adipose and genes associated with obesity
and related traits
Obesity-
related trait
GWAS associated genes with
at least one DM CpG site
GWAS specific trait(s) PMID (PubMed IDs)
BMI and
weight
RASAL2; ADCY3; KCNE4; DGKG; ZNF608; HMGA1;
AIF1; TUB; NRXN3; ADCY9; FTO; SEPT9; MC4R;
FOXN3
Body mass index, Weight; Weight loss
(gastric bypass surgery)
17434869, 18454148, 19079260, 19079261,
20935630, 20966902, 22344219, 22344221,
22982992; 23643386; 23583978, 23563607
Waist
circumference
KCNE4; PPM1H; NRXN3; FTO; MC4R Waist circumference 19557197, 20966902
Metabolic
syndrome
GALNT2; MICB; CAMK2B; TMEM195; TCF7L2;
STOML3; LIPC; PKMYT1; FTO; CETP
Metabolic syndrome, Metabolic syndrome
(bivariate traits)
20694148, 21386085, 22399527
Metabolic
traits
LEPR; ENPEP Metabolic traits 19060910, 21886157
Blood
pressure
CASZ1; CLCN6; CNTN4; MECOM; ENPEP; EBF1;
BAT2; MSRA; CACNB2; C10orf107; PLCE1;
PLEKHA7; FLJ32810; ATP2B1; PTPN11; ACBD4;
PLCD3; MC4R
Blood pressure, Obesity and blood
pressure, Diastolic blood pressure,
Systolic blood pressure, Hypertension
17903302, 19430479, 19430483, 21572416,
21909110, 21909115, 22013104
Cardiovascular KLHL29; TCF7L2; CADM1; APOA4; ATP2B1;
C12orf51; COL4A1; LIPC; SMAD3; CETP; LCAT;
ZFHX3; SMG6; UBE2Z; DNM2; STX16; MRPS6;
FLT1; CUX2; PTPN11
Cardiovascular disease risk factors,
coronary heart disease
17634449, 20838585, 21347282, 21378990,
21943158, 22751097, 23364394
Type-2
diabetes
BCL11A; RBMS1; IRS1, MAEA; AKAP2; CAMK1D;
TCF7L2; GRK5; TCERG1L; KCNQ1; FTO; CMIP;
PALM2; TGFBR3; WISP1; SND1
Type-2 diabetes, Type 2 diabetes and
other traits
17293876, 17460697, 17463246, 17463248,
17463249, 17554600, 17668382, 18372903,
18711366, 18711367, 19056611, 19404141,
19734900, 20174558, 20418489, 20581827,
20862305, 20864672; 21490949, 21573907,
21799836, 22101970, 22158537, 22456796,
22693455, 22931080, 22961080, 23209189,
23300278; 23532257
Blood lipids MACF1; GALNT2; IRS1; AFF1; ARL15; NPC1L1;
DNAH11; PINX1; XKR6; APOA1; APOA4; MYO1H;
C12orf51; LIPC; CETP; LCAT; CMIP; MC4R; NCAN
Cholesterol, Cholesterol total, HDL
cholesterol, LDL cholesterol, Triglycerides
17463246, 18193043, 18193044, 19060906,
19060910, 19060911, 19074352, 19359809,
20031538, 20031564, 20066028, 20686565,
20864672, 21909109, 23505323, 20139978
Adipose
tissue
TP73; KIAA0495; ITPKB; IRS1; LPP; ZNF608;
CNTNAP2; MSRA; BICD2; PRICKLE1; RORA;
SMAD6; FTO
Adiposity, Visceral adipose tissue/
subcutaneous adipose tissue ratio,
Subcutaneous adipose tissue, Visceral fat
19557161, 21706003, 22589738
Blood glucose PROX1; RREB1; TMEM195; TCF7L2; IGF1, FOXN3 Fasting glucose-related traits (interaction
with BMI), Fasting glucose-related traits
20081858, 22581228
Insulin IRS1; SLC10A6; TCF7L2; TCERG1L; IGF1; ATP10A;
LARP6; PCBP3
Fasting insulin-related traits (interaction
with BMI), Insulin-related traits, Fasting
insulin-related traits, Proinsulin levels,
Insulin resistance/response
20081858, 21873549, 21901158, 22581228,
22791750
Genes were identified as associated with obesity and related traits in the GWAS catalogue [49].
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to annotated loci (Additional file 3) in further detail we
observed other genes with known and potential roles in
obesity and related traits (such as PRKCZ, NDUFS2,
GATA2, FOXP2, ANGPT2, NCOR2, CPT1B, PTPN6).
Notably DMRs were also observed in two brown adipose
related genes PRDM16 and Acot11. In addition, we ob-
served DMRs encompassing loci for miR429, miR657,
miR338 and miR199A and antisense RNA locus, EMX20S
(Additional file 3).
None of the 11 genes showing robust differential methy-
lation in omentum mapped to entries in the GWAS cata-
logue or candidate loci listed by McCarthy [15]. However,
4/11 have known or potential roles in obesity, MYO1C,
PLIN4, PARD3 and PDE7B [50-62].Differential methylation of genes involved in epigenome
regulation
DNA methylation and histone modification are two epi-
genetic mechanisms and we observed differential methy-
lation of a number of genes involved in these processes.
DNA methyl-transferases actively methylate cytosines in
CpG dinucleotides. In subcutaneous adipose we saw
differential methylation of two CpG sites within DNA
methyl-transferase DNMT3A (Δbeta 0.11, 0.08) and
DNMT3L (Δbeta 0.09) which can act with DNMT3A to
stimulate de novo methylation, and also interacts with
histone deacetylase 1. Furthermore we observed differ-
ential methylation of one CpG in MBD4 (Δbeta 0.08), a
methyl-CpG-binding domain protein and DNA glycosy-
lase with excision activity against 5-methyl cytosine. In
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and HDAC10 (Δbeta 0.06) were more methylated before
weight loss, with HDAC4 showing a mixed differential
methylation signature, two CpG sites hypermethylated
(Δbeta 0.09, 0.10) and one hypomethylated (Δbeta
−0.11) before weight loss. Differential methylation was
not observed for any genes encoding other histone
modification enzymes.
None of the 11 genes with robust differential methylation
in omentum encode known DNA methyl-transferases,
DNA demethylation enzymes or histone modification
enzymes.
Differential methylation of homeobox genes
Metabolic risk is affected by both the distribution of
body fat between different adipose tissue depots within
an individual and the differing natures of the depots
themselves [9-11]. Homeobox containing genes play a
key role in the development and function of tissues, and
one class of homeobox genes, HOX, in particular have
been shown to be expressed in adipose tissue in a depot
specific manner [63]. Therefore, we investigated differ-
ential methylation of CpG sites within HOX, and also
PAX, MSX and EMX homeobox-containing genes.
In subcutaneous adipose differential methylation of mul-
tiple CpG sites within 3/4 HOX gene clusters was observed:
HOXA4 (three CpG sites Δbeta 0.09, 0.07, 0.07) and
HOXA3 (two CpG sites Δbeta 0.21, 0.12) on chromosome
7; HOXB1 (Δbeta 0.11), HOXB3 (Δbeta 0.12) and HOXB6
(two CpG sites Δbeta 0.13, 0.11) on chromosome 17; and
HOXD4 (four CpG sites Δbeta −0.13, −0.14, −0.19, −0.14)
and HOXD3 (Δbeta −0.18) on chromosome 2. Differen-
tial methylation was also seen for single CpG sites in
MSX1 (Δbeta −0.15) and anti-sense transcript EMX20S
(Δbeta −0.12) which overlaps EMX2. Furthermore, we
also observed DMRs showing hypermethylation before
weight loss within HOXA3 (Chr7:27153534–27153784,
5′UTR), HOXC4 (Chr12: 54409141–5447404, TSS1500,
and Chr12: 5447099–5447404, 5′UTR) and a larger DMR
in HOXB6 (Chr17:46681413–46683953, gene body). A
DMR showing hypomethylation before weight loss was
identified in HOXD3 (Chr2:177030029–177030349, 5′
UTR) (Additional file 3).
No differential methylation of homeobox containing
genes was observed for robust differentially methylated
CpG sites in omentum. When a relaxed P value was
used (P <1 × 10−5) only one site in HOXA3 (Δbeta 0.08,
P = 7.3 × 10−6) and another in MSX1 (Δbeta −0.13, P =
7 × 10−6) were seen.
Pathways enrichment analysis for differentially
methylated genes
To investigate the potential biological relevance of the
differentially methylated CpGs we performed initialenrichment analyses of all loci. For subcutaneous
adipose, analyses were carried out on the 1,889 genes to
which the 3,601 CpG sites passing Bonferroni correction
mapped. Enrichment was seen in Gene Ontologies
(GO): phospholipid binding (GO:0005543, 96 genes, P =
4.1 × 10−10); GTPase regulator activity (GO:0005520, 87
genes, P = 5.9 × 10−9); actin binding (GO: 0003779, 70
genes, P = 3.9 × 10−7); Ras protein signal transduction
(GO:0007265, 74 genes, P = 1.1 × 10−6), and insulin-like
growth factor binding (GO:0019838, 10 genes, P = 0.01).
Further pathways showing enrichment included: focal
adhesion (36 genes, 1.9 × 10−13); metabolic pathways (99
genes, P = 2.7 × 10−12); TGFβ signalling (13 genes, P =
6 × 10−6); insulin signalling (21 genes, P = 8.3 × 10−5);
leptin signalling (12 genes, P = 0.0001); and adipogenesis
(14 genes P = 0.026). All P values are Bonferroni adjusted.
We also investigated whether any of the groups of
CpG sites identified by the hierarchical clustering
(Figure 2) showed enrichment. Only clusters contain-
ing >70 genes were included (7/13) and enrichment
for glucoronidation, insulin and EGF/EGFR signalling,
TGFβ and AMPK signalling, lymphocyte and T cell
apoptosis, cell signalling and plasma membrane was
observed.
Given that DNA methylation and DNA demethylation
are regulated by different mechanisms we also separated
the loci according to whether they were relatively hyper-
or hypomethylated before gastric bypass and weight loss.
GO analysis revealed that hypomethylated loci were
enriched for immune response-related function (for ex-
ample, GO: 0006955, P = 0.0001) which was not seen for
the hypermethylated genes; these showed enrichment
for phospholipid binding, actin binding and GTPase
regulator activity as above.
Due to the small number of CpG sites passing Bonferroni
correction in omentum we used the more relaxed threshold
(P <1 × 10−5) for enrichment analyses (920 unique genes to
which 1,347 CpG sites mapped). GO enriched were:
GTPase regulator activity (GO: 0030695, 53 genes, P =
1.6 × 10−8); actin cytoskeleton (GO: 0015629, 33 genes, P =
0.009) and phospholipid binding (GO: 0005543, 41 genes,
P = 0.015). Enriched pathways included focal adhesion (15
genes, P = 2.5 × 10−5) and insulin signalling (10 genes, P =
0.008). All P values are Bonferroni adjusted.
Hierarchical clustering of the CpG sites passing the re-
laxed threshold in omentum revealed 15 clusters, five of
which had >70 genes. Enrichment for GTPase regulator
activity, G-protein signalling and TGFβ and insulin
signalling was observed.
Separation of the loci into those hyper and hypo methyl-
ated before gastric bypass revealed enrichment for 2/60
hypo-methylated loci (SORT1 and PCSK6, related to nerve
growth and neutrophin binding, GO: 0048406 and GO:
0043121, respectively). The hypermethylated loci were
Benton et al. Genome Biology  (2015) 16:8 Page 10 of 21enriched for GTPase regulator and related activities also
seen in the subcutaneous adipose analysis.
Environmental factors involved in differential methylation
of adipose tissue
Clinical blood measures (such as elevated fasting glu-
cose, insulin and lipids) are not only indicators of disease
risk but also provide an indication of the internal body
environment. Therefore, potential relationships between
changes in methylation and changes in 11 clinical vari-
ables (weight, BMI, fasting glucose, insulin, blood lipids
(HDL, LDL, triglycerides, total cholesterol), HbA1c, and
systolic and diastolic blood pressure) were investigated
using Pearson’s correlation. In order to maximise the
likelihood of identifying robust correlations we filtered
our analysis at absolute R >0.75 and P <0.05 (Benjamini
Hochberg [64]). Of the 1,889 annotated loci to which the
3,601 CpG sites passing Bonferroni correction mapped we
observed correlations between methylation in 40 genes
and at least one clinical trait (Additional file 4). Correla-
tions between genes and weight loss were observed in two
genes with known roles in obesity: FOXP2 (cg18546840
R = 0.85) and ACSL1 (cg00287477 R = 0.91). A correlation
between change in methylation and weight was also seen
for CELSR1 (cg06652313, R = 0.82). In addition, methyla-
tion changes at a number of loci which did not show a
strong correlation with weight loss did show strong,
independent correlations with other clinical traits such
as fasting glucose (Additional file 4). With Δfasting glu-
cose we observed correlations with change in DNA
methylation for HDAC4 (cg26078407 R = −0.75) and
SLC37A3 (cg15751131 R = −0.80). In addition, a correl-
ation between DENND1C (cg11599981) and both fast-
ing glucose and HbA1c (R = 0.75 and 0.85, respectively)
was seen.
An interrogation of the 15 CpG sites from omentum
did not reveal any correlations passing stringent filtering,
or at a more relaxed R >0.5.
Technical validation and extension of DNA methylation
analyses
We analysed a number of loci using an independent
DNA methylation assay, pyrosequencing, in the 15 indi-
viduals from the array experiment. Six genes/loci were
selected from the subcutaneous adipose analysis based
on a number of criteria: (1) most hyper- and hypomethy-
lated before and after weight loss (CMIP and IFFO1, see
Table 3); (2) genes implicated in obesity and/or type-2 dia-
betes (KCNQ1, CETP, CMIP, ADRAB2); and/or (3) reported
differential adipose mRNA expression in response to weight
loss/dietary intervention (CETP, CTGF). All CpG probe
sites passing Bonferroni correction in a given gene were
analysed. Correlation between the two types of methylation
assay for all 15 sites interrogated was good (R2 = 0.656-0.939, P = 3.6 × 10−8 - 9.8 × 10-19, Additional file 5). Figure 5
presents data for four representative CpG loci.
For omentum we selected the CpG probe sites in the
four genes with known or potential roles in obesity
MYO1C, PLIN4, PARD3 and PDE7B. Significant correla-
tions between methylation measures was observed for
PDE7B (R2 = 0.671, P = 1.9 × 10−8), PLIN4 (R2 = 0.399, P =
0.0001) and PARD3B (R2 = 0.528, P = 2.4 × 10−6). Differen-
tial methylation of MYO1C did not validate (R2 = −0.02,
P = 0.49) although the original assay failed and the second
design did not seem as robust as other assays.
DNA was also available from samples taken before and
after weight loss for an additional 12 individuals for
subcutaneous adipose (9 men, 3 women) and an additional
seven for omentum (5 men, 2 women). A combined ana-
lysis of the original samples and extended cohort revealed
significant differential methylation of all 15 CpG sites
interrogated in subcutaneous adipose in women and men
except two CpGs in KCNQ1 which were not differentially
methylated in men (Additional file 6). A comparison of
methylation at each CpG between men and women
revealed small but statistically significant differences
(P <0.05) at a number of loci (Additional file 6). Notably,
six CpGs within an island in CMIP all showed statistically
more methylation in women than men after weight loss as
did three adjacent CpG sites in CETP.
In omentum the CpG loci within PARD3B, PDE7B and
PLIN4 showed differential methylation before and after
weight loss in men and women except one CpG site
located 7 bases upstream of the transcription start site of
PDE7B (Additional file 7). None of the CpG loci within
PARD3B, PDE7B and PLIN4 showed a significant diffe-
rence in methylation level between men and women
(Additional file 7).
mRNA analysis of differentially methylated genes
DNA methylation is known to affect transcription [65].
Therefore we wanted to examine mRNA expression of
genes to which the differentially methylated CpG sites
mapped. Because of the number of CpG sites passing
multiple testing adjustment, we chose to limit our ana-
lysis to those located in gene promoter regions. Defining
promoter regions broadly as the 5′UTR, or within 1,500
bases upstream of the transcription start site (5′UTR,
TSS200 and TSS1500 as per Illumina annotation) we
identified 777/1,889 genes in subcutaneous adipose with
differential methylation in their promoter regions. We
selected five of these (ACACA, CETP, CTGF, S100A8,
S100A9) for further analyses based on reported adipose
or adipocyte gene expression changes in response to
weight loss/dietary intervention (ACACA, CETP, CTGF
[66-69]), and/or associations with obesity or related
traits (GWAS, and/or other literature). CTGF, S100A8
and S100A9 were upregulated and CETP downregulated
20 30 40 50 60 70 80
0.
2
0.
3
0.
4
0.
5
0.
6
0.
7
0.
8
Pyrosequencing (% Methylation)
Ill
um
in
a 
45
0K
 (
B
et
a)
CETP_cg03232842
R 2 = 0.834
p = 1.2e−12
20 30 40 50 60 70 80
0.
2
0.
3
0.
4
0.
5
0.
6
0.
7
0.
8
Pyrosequencing (% Methylation)
Ill
um
in
a 
45
0K
 (
B
et
a)
CMIP_cg02573873
R 2 = 0.842
p = 5.9e−13
20 30 40 50 60 70 80
0.
2
0.
3
0.
4
0.
5
0.
6
0.
7
0.
8
Pyrosequencing (% Methylation)
Ill
um
in
a 
45
0K
 (
B
et
a)
IFFO1_cg10838410
R 2 = 0.812
p = 6.7e−12
20 30 40 50 60 70 80
0.
2
0.
3
0.
4
0.
5
0.
6
0.
7
0.
8
Pyrosequencing (% Methylation)
Ill
um
in
a 
45
0K
 (
B
et
a)
KCNQ1_cg03371125
R 2 = 0.873
p = 2.9e−14
Figure 5 Correlations between Illumina 450 K array data and pyrosequence analysis. Representative data for a single CpG site in four
genes are shown. Red indicates samples taken before and blue after gastric bypass. Illumina probe IDs are indicated after gene names.
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S100A9 and CETP was negatively correlated with DNA
methylation, that is less expression was observed with
more methylation, whereas mRNA levels of CTGF were
positively correlated (Table 6).
Two of 11 genes identified in omentum had differential
methylation within their promoter regions (PLIN4,
GALK2). PLIN4 was selected for further investigation
because it is associated with obesity, insulin resistance and
increased blood lipids [55-60,70]. mRNA expression was
upregulated before compared to after weight loss, as was
methylation (Table 6). As we had pyrosequence for six CpG
sites immediately upstream of the PLIN4 transcription start
site we averaged the percent methylation across this region
and tested for a correlation (linear regression) with mRNA
expression both before and after weight loss. Interestingly
we observed a strong correlation after weight loss (R2 =
0.55, P = 0.0009) with decreased methylation corresponding
to increased mRNA expression whereas no correlation was
observed before weight loss (R2 = −0.03, P = 0.5).Discussion
This study revealed significant changes in DNA methyla-
tion in two distinct abdominal adipose tissue depots be-
fore and after gastric bypass and associated weight loss.
Global DNA methylation was greater in subcutaneous
adipose and omentum before weight loss (Figure 1). This
observation is intriguingly in concordance with another
comparison before and after gastric bypass, but in skeletal
muscle [45], despite the fact that numerous factors could
be influencing the global shift such as cell heterogeneity,
and environmental changes like metabolic status, lifestyle
and diet. It is also possible that this hypomethylation in
different tissues after gastric bypass reflects an effect of
gastric bypass specifically and/or the profound level of
weight loss. This is particularly interesting given the
observation that after 6 months exercise intervention in
non-obese male individuals an increase in global DNA
methylation of thigh subcutaneous adipose was ob-
served [40]. These contrasting observations potentially
highlight important differences between adipose tissue
Table 6 mRNA expression and DNA methylation in subcutaneous adipose and omentum
Gene Adipose tissue log2 fold change expression
before vs. after weight loss
T statistic P value Δ DNA methylation
before vs. after weight loss
Methylation probe location
ACACA Subcutaneous −0.82 4.02 0.001 −0.17 5′ UTR
CETP Subcutaneous −2.48 5.49 0.00008 0.15 TSS1500
CTGF Subcutaneous 0.94 3.72 0.002 0.14, 0.12 TSS1500
S100A8 Subcutaneous 2.49 4.46 0.0005 −0.12 5′UTR
S100A9 Subcutaneous 2.23 4.18 0.0009 −0.12 5′UTR
PLIN4 Omentum 0.89 4.86 0.0002 0.04 TSS200
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example, abdominal vs. thigh, near or distant from greatest
reduction in adipose tissue mass, non-obese vs. obese),
cellular complexity and functional response to weight loss
and/or exercise. Furthermore, DNA demethylation (as
evidence by relative hypomethylation) can occur by both
active and passive mechanisms [71]. In proliferating cells
passive loss of methylation can result from successive
rounds of replication in the absence of restoration of CpG
methylation by DNMT1 UHFR1, or an initial active oxida-
tion of methylated cytosine followed by replication-
dependent dilution [71]. We did observe decreased methy-
lation after gastric bypass and weight loss within one DNA
methyl-transferase DNMT3A, and its co-factor DNMT3L
as well as within the gene for MBD4 a methyl-cytosine
binding protein and DNA glycosylase. Unfortunately, an as-
sessment of DNA replication in our tissue samples was not
possible, but the relative contribution replication rate differ-
ences may play both in the tissues before and after weight
loss and in the different cell types warrants further investi-
gation. Such studies will be particularly important given the
additional, recent observation that changes in the metabolic
state of cells may affect the levels of enzymatic co-factors
involved in active DNA demethylation [72].
The tissues we have examined are by their very nature
of mixed cell composition, and this is integral to their
function [73]. Adipose tissue contains many different
cell types including adipocytes that make up about 20%
to 40% of the total cellular content, and fibroblasts, pre-
adipocytes, stem cells and immune cells. This cell milieu
will change significantly on weight loss. As evidenced by
the pathways enrichment and DMR analyses (Figure 4) a
proportion of the observed DNA methylation changes
are likely to reflect these changes in cellular composition.
While some of these cell-proportion related changes might
be seen as bystander effects it is important to recognise that
others may highlight important biological and functional
differences related to disease. Furthermore, analysis of
epigenetic marks, such as DNA methylation, which play a
key role in cell development and differentiation, may have
increased utility to uncover previously undetected cell-type
specific differences of relevance to biology. In addition, we
observed differential methylation of a significant number ofobesity related genes (not only related to tissue remodelling,
or inflammation) which we believe supports our approach.
Future analyses which focus on particular cell types,
such as adipocytes and adipose tissue macrophages, and
their relative contribution to disease will no doubt yield
additional insights. As it is not always possible to access
human tissue samples with sufficient speed or of suffi-
cient quantity to isolate specific cell types, algorithms
currently being developed by a number of groups to
deconvolute cell mixtures in DNA methylation analysis
[74-76] will hopefully provide additional insights from
whole tissue samples.
Our analysis revealed distinct differences in the level
of differential methylation observed for subcutaneous
adipose and omentum. One hundred and ninety-five
extended DMRs, and robust differential methylation of
3,601 CpG sites were identified in subcutaneous adipose,
in comparison to omentum where no DMRs and 15 dif-
ferentially methylation CpGs were observed. Subcutane-
ous abdominal adipose can expand significantly to store
excess lipid and act as a potential buffer protecting other
organs and adipose tissue depots from lipid accumula-
tion [7,8]. Thus, the magnitude in terms of both number
of differentially methylated loci and degree of difference
(up to 27.4% (Table 2)) we observed potentially reflects the
function (and relative plasticity) of this tissue and the large
reduction in adipose tissue mass and inflammatory cells, as
well as tissue remodelling, that would occur with profound
weight loss; a hypothesis supported by the pathways ana-
lyses. In addition, the pathways analysis highlighted differ-
ences between relatively hyper- and hypomethylated loci
before weight loss. Genes involved in the immune response
were enriched in the hypomethylated group, potentially
reflecting a larger proportion of immune cells in this tissue
depot before weight loss.
Expansion of omentum is associated with increased risk
of metabolic dysfunction [12-14]. Our observation of sig-
nificantly less differential methylation in omentum may be
indicative of the different function of this organ and that it
is potentially more tightly controlled with less tolerance
for disruption. Therefore, it is interesting that the path-
ways analysis of differentially methylated loci passing a
relatively relaxed P value in omentum (P = 1 × 10−5) and
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of GTPase regulator activity as seen for subcutaneous
adipose where the more robust cutoff was used. Adi-
pose tissue is an endocrine organ and has the ability to
communicate with other cell types and alter the behav-
iour of cells within its vicinity [73]. The differences
between the two tissues studied here is likely to reflect
this; one notable difference being that blood supply to
the omentum drains directly into the hepatic portal
system and is delivered directly to the liver, another
highly metabolic organ.
Four of the 11 genes each with a single differentially
methylated CpG site in omentum have known or poten-
tial roles in obesity. MYO1C is an actin-based motor
protein involved in GLUT4 translocation, and insulin-
dependent actin filament remodelling [51-53,56,61]; a
SNP variant in PARD3 has been associated with type-2
diabetes [50]; members of the PDE7B gene family
(PDE3B in particular) play a central role in the regula-
tion of lipolysis, lipogenesis and glucose uptake [54,62],
and SNP variants in PLIN4 have been associated with
obesity, insulin resistance and increased blood lipids
[55,57-60]. This raises the question as to which of the
remaining 7/11 genes (LBP, RXRB, CPLX1, GLAK2,
CSTL1, SLC9A3, CA12) may also have a role in obesity.
Furthermore, given our observation of differential
methylation of a single CpG within the PLIN4 promoter
(Table 4) we performed mRNA analysis and observed in-
creased expression before weight loss, consistent, all be
it in a different tissue, with the observation that PLIN4
knock-down in mice resulted in less lipid accumulation
in cardiac tissue [77]. DNA methylation within promoter
regions is associated with transcriptional repression [65].
A strong correlation in agreement with this was ob-
served between average methylation across 6 CpG sites
adjacent to the PLIN4 transcription start site (pyrose-
quencing) and mRNA expression in omentum after
weight loss whereas no such correlation was seen for
pre-gastric bypass tissue. This may reflect a dysregula-
tion of ‘normal’ PLIN4 control in the obese omentum.
To our knowledge this is the first report for a potential
role of DNA methylation in the regulation of obesity
associated gene PLIN4.
Few studies have looked at DNA methylation in omen-
tum. Methylation of nine CpG sites in the gene body of
DPP4 (exon 2: Chr2:162929997–162929799. Map position
as genome build 37/hg19 throughout manuscript) in vis-
ceral adipose tissue (sampled from the greater omentum)
has been associated with increased plasma lipid [78].
DPP4 is thought to play a role in glucose homeostasis and
type-2 diabetes by inactivating incretin hormones involved
in glucose-dependent insulin secretion [79,80]. We saw
hypermethylation of one CpG in the body of DPP4
(Chr2:162927003, 2,796 bases away from the sitesidentified above) using a relaxed threshold before weight
loss (Δbeta 0.106, P = 3.7 × 10−6). Given that plasma lipid
profile and weight decrease after gastric bypass our results
are consistent with the previously observed association
with plasma lipid [78], highlighting the potential role of
DNA methylation in DPP4 regulation in omentum for
further investigation.
A total of 3,601 individual CpG sites showed signifi-
cant differential methylation in subcutaneous adipose
tissue, mapping to 1,889 unique annotated loci as well as
intergenic regions. Thus, for the majority of annotated
loci we observed differential methylation at a single CpG
within the gene. As a stringent statistical threshold was
used selection of candidates for future analyses would
benefit from an interrogation of the methylation profile
of other Illumina probes within the gene of interest at a
more relaxed threshold, as well as indications from the
literature (such as those discussed below) with respect
to previously reported DNA methylation variation and/
or a potential role of biological relevance.
In subcutaneous adipose 120/1,889 differentially methyl-
ated loci have been associated with obesity or related traits
in GWAS (Table 5), and we saw changes in single CpG
sites within 9/57 previously defined obesity genes [15].
Furthermore, Rönn et al. recently reported differential
methylation of a number of obesity candidate loci in thigh
subcutaneous adipose after exercise; we observed differen-
tial methylation at single CpG sites within four of these:
NRXN3 (Δbeta 0.03, Chr14: 79747774), STAB1 (Δbeta
0.12, Chr3: 52553167), TUB (Δbeta 0.11, Chr11: 8084670),
ZNF608 (Δbeta 0.15, Chr5: 124013536). While Rönn et al.
did not observe a significant change in BMI they did re-
port a decrease in waist circumference and waist/hip ratio
after exercise intervention which suggests a reduction in
abdominal adipose mass. Assuming in this case that post-
exercise is equivalent to after gastric bypass the direction
of DNA methylation change is consistent between the
studies for TUB (Δbeta equivalent 0.034. 11:8102717,
18 kb from CpG site identified in our study) with a greater
magnitude of change observed after gastric bypass. In con-
trast the single CpG sites identified as differentially meth-
ylated by Rönn et al. in NRXN3, STAB1 and ZNF408
changed in the opposite direction with relative hyperme-
thylation after exercise intervention. The individual CpGs
in NXRN3 and ZNF608 were at some distance (>50 kb)
from those identified in this study, whereas the sites in
STAB1 are located within 118 bases of each other. This
highlights the differences between the study designs (as
discussed above), the challenges of interpreting the signifi-
cance (or not) of robustly identified differential methyla-
tion of single CpG sites within genes using genome-wide
platforms, and the incompletely understood complexity of
the role of DNA methylation in transcriptional regulation;
as well as the importance of subsequent validation, more
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and evidence. This said, the identification of individual
CpGs can have real utility for highlighting potential genes
of interest as illustrated above for PLIN4 in omentum
where our subsequent pyrosequencing revealed differen-
tial methylation of a further five CpGs in the promoter
region (Additional file 7) and mRNA analyses revealed
changes in gene expression.
At least 4/15 genes containing ≥6 differentially methyl-
ated CpG sites had a potential role in obesity and/or
related traits (PRKCZ, PRDM16, FOXP2, THBS1 [81-89]).
The DMR analysis also identified extended regions of dif-
ferential methylation in PRKCZ, PRDM16 and FOXP2.
PRDM16 is of interest and potentially worth further inves-
tigation given its role in activating the adipogenesis of
brown adipose tissue. Relative hypermethylation was ob-
served before gastric bypass and weight loss within a CpG
island located in the body of PRDM16 (Chr1:305660–
3056758). Brown adipose catabolises lipids to produce
heat and was thought to essentially disappear in the first
year after birth. With the recent discovery that adults
retain metabolically active brown adipose tissue has
come the suggestion that this tissue could provide a
promising target with which to combat obesity [89,90].
A DMR was also identified in the gene body of ACOT11
(Chr1: 55088744–55089810) which is enriched in brown
adipose tissue and ACOT11 knock-out mice are resist-
ant to diet-induced obesity and show increased energy
expenditure [91,92].
Genes in the HOX networks are expressed in adipose
tissue and appear to have a role in metabolic dysfunction
[63]. DNA methylation is known to affect transcription
[65], with changes often observed within and adjacent to
promoter regions. Of the five DMRs identified within
HOX genes in this study three were located in 5′ UTR
regions (HOXA3, HOXC4, HOXD3) and a second DMR
was located within 1,500 bases of the TSS of HOXC4.
While our study was not designed or aimed at identi-
fying type-2 diabetes specific DNA methylation, obesity
is a significant risk factor for this disease, and type-2 dia-
betes is substantially reduced in patients after gastric by-
pass [43,44,93,94]. Therefore, we note that we identified
differential methylation of single CpG sites within 7/59,
two CpG sites in 2/59 (BCL11A, AKT2), and consistent
changes in six CpG sites in 1/59 (KCNQ1) type-2 dia-
betes genes [15]. A DMR was also identified within one
of these, PROX1. Our observation of increased methyla-
tion within KCNQ1 at 4/6 CpG sites within 258 bases of
each other in TSS1500 (Δbeta 0.061-0.104, cg03371125,
cg04902871, cg196988309, cg10678459) and two other
CpG sites (cg19923326, cg14637411) and FAP (1 CpG,
Δbeta 0.203, TSS200, cg08826839) before weight loss is
consistent with a study of subcutaneous adipose in
monozygotic twins; increased methylation in the diabetictwin was reported close to the site of differential methy-
lation we observed for FAP at TSS + 86. In KCNQ1 they
reported increased methylation in the diabetic twin of a
single CpG site (cg19728223, Δbeta equivalent 0.074)
located in the gene body >15 kb away from the closest
site identified in our analysis (cg19923326) [39]. We also
technically validated our observations for KCNQ1 by
pyrosequencing analysis of the original cohort, and
extended this to an additional 12 samples (3 women, 9
men). Interestingly we did not observe significant differ-
ential methylation of 2/15 CpG sites interrogated in men
(Additional file 6), an observation which may warrant
further investigation in a larger cohort with mixed
gender. In addition, differential methylation of type-2
diabetes genes in thigh subcutaneous adipose tissue after
exercise intervention was recently reported [40]; we ob-
served differential methylation within five of these. Rönn
et al. reported increased methylation after exercise inter-
vention of 8/10 and 1/6 CpG sites in KCNQ1 (Δbeta
0.015-0.045) and TCF7L2 (Δbeta 0.011-0.046), respect-
ively (with decreased methylation of the other sites) and
a single CpG site in each of BCL11A (cg01865786, Δbeta
0.03), FTO (cg26580413, Δbeta 0.033) and PROX1
(cg01902845, Δbeta 0.042); these CpG sites were located
in the gene body of each loci. Consistent with this we
observed hypomethylation of the same CpG site within
FTO (cg26580413, Δbeta −0.11). For all other CpGs in
these genes we observed hypermethylation before weight
loss: within KCNQ1 at 4/6 CpG sites within 258 bases of
each other (TSS1500, Δbeta 0.061-0.104, cg03371125,
cg04902871, cg196988309, cg10678459) and two other
CpG sites (cg19923326, cg14637411); a single site in
TCF7L2 (cg15624624, Δbeta 0.106); two CpG sites
within 15 bases of each other in BCL11A (cg23556108,
cg22445742, Δbeta 0.15, 0.16), and a DMR in PROX1. Most
of these sites were not located close to those reported by
Rönn et al., except the DMR in PROX1 which was 254
bases away (DMR: Chr1: 214169676–214170679,
cg01902845 - Chr1:21470933). As discussed above the
similarities and contrasts of the two studies highlight
differences in experimental design, the challenges of
genome-wide methylation profiling, the complex role
of DNA methylation in transcriptional regulation, and
the importance of further validatory and in-depth
analyses.
A recent study observed and replicated a positive asso-
ciation between DNA methylation in blood at three
CpG sites within HIF3A (cg22891070, cg27146050 and
cg16672562) and BMI [95]. They then analysed data
available for subcutaneous adipose tissue and skin,
reporting that methylation at cg22891070 was associated
with BMI in adipose, but not skin tissue. Consistent with
this observation we saw increased methylation at HIF3A
(cg228910710) before gastric bypass and weight loss
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These observations raise a couple of points. First, that
an epigenetic mark associated with BMI and potentially
obesity (DNA methylation of cg22891070 in HIF3A)
may be modifiable, in this case by gastric bypass and or
weight loss, and thus, if appropriate, may be tractable to
treatment. Second, that blood may have utility as a sam-
ple for obesity-related epigenetic biomarker analyses,
acting as a surrogate for identifying potentially tissue
specific changes of relevance to disease. In this regard, a
number of other studies looking at obesity and related
traits have profiled global DNA methylation in blood
and reported that methylation: co-varies with BMI in
blood lymphocytes [25]; shows obesity-related changes
in blood leukocytes [26], varies in association with
type-2 diabetes [31]; and shows correlations with diet-
induced weight loss in peripheral white blood cells [29].
Associations between methylation status in whole blood
at birth and body size in childhood have also been re-
ported [96]. We observed an overlap with some of the
loci identified in these studies. DNA methylation within
ATP10A increased (Δbeta equivalent 0.025) within a 98
base region of the gene body (Chr15:26026249–26026347)
in peripheral blood mononuclear cells from obese or over-
weight men after an 8-week low-calorie intervention [29].
Consistent with this, we observed increased methylation
(Δbeta −0.14) of one CpG site in ATP10A (cg20049422,
Chr15:26044289) in subcutaneous adipose after significant
weight loss, although this site is nearly 18 kb from that re-
ported in blood. Variable methylation of MMP9 has been
associated with lean mass in cord blood [96] and with
BMI in blood lymphocytes [25]. We observed increased
methylation before weight loss (Δbeta 0.09) of a single CpG
site within MMP9 (cg04656101, Chr20:44645014) which is
consistent with the observation of Feinberg et al. [25] who
reported a positive correlation between methylation in or
near MMP9 and BMI [25]. In addition, increased methyla-
tion of three CpGs in KCNQ1 (Chr11:2849340–2849503,
Δbeta 0.016-0.029) and decreased methylation of one CpG
in FTO (Chr16:53809231, Δbeta 0.026) was observed in
peripheral white blood cells of type-2 diabetics in a case–
control study [31]. In line with this, though at some
distance from the sites described above, we observed both
increased methylation of six CpG sites in KCNQ1 (4 CpGs
Chr16:2464845–2465103, TSS1500, Δbeta 0.061-0.104, two
CpG sites Chr: 16:2828778, Δbeta 0.08, Chr16:2858355,
Δbeta 0.10) and decreased methylation of FTO (Δbeta
−0.113, Chr16: 54025348) before weight loss. Given the dif-
ferences between blood and adipose tissue it is tempting to
speculate that maybe such similarities reflect a whole body
or intra uterine response to the obese environment, and/or
an inherited epigenetic signature. Also, it arguably provides
additional evidence for the utility of blood studies for both
the investigation of epigenetic mechanisms at play inobesity, and identification of epigenetic biomarkers of
disease; possibilities that warrant further investigation.
Clinical parameters measure changes in the body and
blood environment. Tissues exist within this environ-
ment, and the epigenome is highly dynamic changing in
response to environmental stimuli, such as nutrient
availability [19-23,37], and physical exercise [40]. In this
context we interrogated changes in DNA methylation at
individual CpGs in subcutaneous adipose and clinical
trait, and observed correlations passing a robust thresh-
old of absolute R >0.75 and adjusted P <0.05 (Benjamini-
Hochberg) for sites in 40 genes and at least one clinical
measure (Additional file 4). While each correlation is be-
tween a single CpG site and a clinical parameter potential
significance is suggested by the presence of correlations
between genes with biological relevance to the trait.
Changes in methylation at single CpGs within FOXP2
(cg26580413, Δbeta 0.21) and ACSL1 (cg00287477, Δbeta
0.09) were correlated with changes in weight (FOXP2 R =
0.85 and ACSL1 R = 0.91). Copy number variants in
FOXP2 have been associated with childhood obesity [83]
and nominally associated with obesity in a familial case–
control study [97]. ACSL1 encodes long-chain acyl CoA
synthetase 1 an enzyme which catalyzes thioesterification
of fatty acids and knock-down of this gene in 3 T3-L1 adi-
pocytes suppressed lipogenic genes, and increased ex-
pression of TNFα and IL6 [98]. A correlation between
change in fasting glucose and methylation within HDAC4
(cg26078407, Δbeta −0.11) was observed (R = −0.75). This
is interesting given that HDAC4 is a class II histone deace-
tylase which is reported to downregulate GLUT4 tran-
scription in cultured adipocytes and fasting mice [99], and
that downregulation of the HDAC4 protein was recently
reported in obese subjects with expression induced by
exercise [100]. Furthermore, differential methylation and
mRNA expression of HDAC4 was observed in thigh sub-
cutaneous adipose after exercise intervention [40]. The au-
thors also silenced HDAC4 in 3 T3-L1 adipocytes showing
that HDAC4 repression appeared to result in increased
lipogenesis. We also observed a correlation between
change in DNA methylation in SLC37A3 (cg15751131,
Δbeta −0.10), a sugar-phosphate exchanger for which an
association with congenital hyperinsulinemia has recently
been reported [101], and fasting glucose (R = −0.80). Per-
haps most intriguingly we observed a correlation between
changes in DNA methylation in DENND1C (cg11599981,
Δbeta 0.12) and both fasting glucose (R = 0.75) and HbA1c
(R = 0.85). Little is known about DENND1C which is a
member of a class of DENN domain Rab GDP-GTP ex-
change factors (GEFs) [102]. Different GEFs can bind the
same Rab protein and appear to modulate Rab activity to-
ward different cellular functions [104]. DENND1C can act
as a GEF for Rab35 [103,104], and Rab35 has been shown
to play a role in insulin stimulated GLUT4 trafficking in
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future investigation of DENND1C may be warranted to ex-
plore a potential role in glucose transport and homeostasis.
The potential significance of our data is further supported
by our observation of significant differential mRNA expres-
sion of five genes (ACACA, CTGF, S100A8, S100A9 and
CETP) showing differential promoter methylation in sub-
cutaneous adipose (Table 6). All these genes are of potential
biological significance: mRNA expression of ACACA and
CTGF in adipose tissue is regulated by caloric intake
[67,68] and upregulation of CTGF was observed in sub-
cutaneous adipose in a model of dietary induced obesity
[106]; differential expression of CETP during weight loss
and maintenance was recently reported [69]; and the prod-
ucts of S100A8 and S100A9 form the calprotectin complex,
a biomarker of obesity, for which increased circulating
levels are associated with abdominal obesity, and adipose
and systemic tissue inflammation [107-109].
Our study was necessarily constrained by its clinical
nature: the sample size, and rare occurrence of repeat
operation after gastric bypass, but we believe significant
strength is provided by the paired nature of the analyses
which reduces the effects of inter-individual variability.
Also, gastric bypass achieves major, sustained weight
loss and improvement of many obesity co-morbidities
[43,44,93,94]; as such we consider it a model akin to an
extreme phenotype approach which should increase
the chance of identifying biologically relevant changes
associated with obesity, its related co-morbidities and
weight loss. We believe our data support the validity of
this approach as evidenced by our observation of differ-
entially methylated loci passing robust multiple testing
adjustment which: are present not only in genes in-
volved in obesity and type-2 diabetes, but loci previ-
ously reported to show variable DNA methylation in
associated phenotypes; are located in the promoter
regions of genes showing differential mRNA expression;
show consistent effect over extended regions which sup-
ports their potential biological relevance, and show cor-
relations between differential methylation and changes
in clinical trait.
Conclusions
Here we report significant changes in the DNA methy-
lome of two adipose tissue depots (subcutaneous adipose
and omentum) after gastric bypass and weight loss. To
our knowledge this is the first study to report global
DNA methylation profiling of both adipose tissues be-
fore and after major weight loss. While it does not allow
a distinction between cause and effect with regard to
weight loss, it provides additional support of previously
reported observations of DNA methylation changes as-
sociated with obesity and related traits, suggesting that
this mechanism plays a key role in the biology of obesity.It also highlights additional loci with a potential role in
disease as good candidates for future analyses. Further-
more, it suggests the possibility that epigenetic tissue re-
modelling of obesity genes in response to gastric bypass
may occur. Thus, the study provides a solid basis for
future work and offers further support for the role of
adipose tissue DNA methylation in obesity.
Materials and methods
Sample inclusion
All subjects gave their written informed consent; The
Central Regional Ethics Committee, Wellington, New
Zealand approved the study, which complied with the
Helsinki Declaration for human research.
The subjects included 15 obese women who under-
went gastric bypass by a single surgeon at Wakefield
Hospital, Wellington, New Zealand and who returned
for a second operation (incisional hernia repair (n = 8),
incisional hernia repair and abdominoplasty (n = 4), silas-
tic ring removal (n = 2) or roux loop lengthening (n = 1).
Individuals had lost at least 27% of their original body
weight (mean 37%, +/− 7.9) by the time of the second op-
eration, representing a mean decrease in BMI of 18.3 +/−
7.8. Mean time between operations was 17.5 months with
a range of 9 to 31 months. Clinical and anthropometric
data were collected prior to each operation and are sum-
marised in Table 1.
Adipose tissue samples were taken at time of surgery,
immediately snap frozen in liquid nitrogen and stored
at −80 C.
DNA extraction
DNA was extracted from approximately 100 mg of tissue
using a QIAamp DNeasy Tissue Kit (Qiagen) as per the
manufacturer’s protocol, with a 3-h initial lysis step and
RNase treatment. DNA was quantitated using a Nanodrop.
DNA methylation 450 K Illumina BeadChip
Genomic DNA (500 ng) from each sample was treated
by bisulphite conversion with the EZ DNA Methylation
Kit (Zymo Research Corporation, Irvine, CA, USA)
according to manufacturer’s recommendations. A total
of 4 μL of bisulphite converted DNA was analyzed using
Illumina Infinium Human Methylation 450 K BeadChip
Array technology (Illumina, Inc., San Diego, CA, USA)
according to the manufacturers protocol. Beadchips
were scanned using the Illumina HiScanSQ system that
employs a two-colour laser (532 nm/660 nm) fluorescent
scanner with a 0.375 μm spatial resolution. The inten-
sities of the images were extracted using Genome Studio
(2011.1) Methylation Module (v1.8.5). The Illumina Human
Methylation 450 K BeadChip interrogates 485,577 cytosine
positions in the human genome; the majority are CpG di-
nucleotides, with 3,343 CNG sites (throughout the paper
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are located within known gene regions (promoter, gene
body and UTRs [untranslated regions], and 119,830 are
intergenic (see [110]).
DNA methylation pyrosequencing
Genomic DNA samples were sent to a commercial pro-
vider, Exiqon (USA). For genes selected for pyrosequencing
all CpG probe sites passing Bonferroni correction were
interrogated. For subcutaneous adipose tissue these
were: CETP (cg03232842), IFFO1 (cg10838410); CTGF
(cg00516030, cg17359975); CMIP (cg02573873, cg05438708,
cg05705335, cg08344351); and KCNQ1 (cg03371125,
cg04902871, cg10678459, cg14637411, cg19698309,
cg19923326). For omentum: PARD3B (cg12157387);
PLIN4 (cg01907005); MYO1C (cg06579248); and PDE7B
(cg04627183). Depending on the assay, amplicon and
sequence content additional CpG sites surrounding the
loci of interest were also analysed. Pyrosequencing as-
says were designed, optimised, performed and analysed
by Exiqon with both pyrograms and assay result data
supplied.
RNA extraction
Total RNA was extracted from approximately 100 mg of
tissue using Trizol (Invitrogen) as per the manufacturer’s
protocol, with an additional chloroform extraction. RNA
quantity and quality were assessed using a Nanodrop
and Agilent Bioanalyser, respectively. All RNA samples
had an RNA integrity number (Agilent Bioanalyser) >7.
QRTPCR
A total of 500 ng RNA was reversed transcribed using a
SuperScript® VILO™ cDNA Synthesis Kit (Life Technolo-
gies) following the manufacturer’s instructions. QRTPCR
was performed (RocheLight Cycler 480II) using 2 μL 1/5
dilution of cDNA, Perfecta Toughmix (dNature) and Taq-
Man gene expression assays (Life Technologies). Assays
were: CETP (Hs00163942_m1), CTGF (Hs01026927_g1),
ACACA (Hs01046047_m1), S100A8 (Hs00374264_g1),
S100A9 (Hs00610058_m1) and PLIN4 (Hs00287411_m1).
18 s (4319413E) and PPIA (cyclophilin A, 4326316E) were
selected as endogenous controls based on previous gene
expression studies in adipose tissue [66,67,69,111-113].
Data analysis
Analyses were performed using R version 2.15.2 [114],
Bioconductor [115] packages and custom bash scripts.
DNA methylation
Each adipose tissue depot, omentum and subcutaneous
adipose, was treated independently. Raw intensity data
(Illumina 450 K idats) were parsed into the Bioconductor
minfi package [116]. Background correction and controlnormalisation was implemented in minfi. Probes were
classed as failed if the intensity for both the methylated
and unmethylated probes was <1,000 (based on intensities
observed for negative control probes). Any probe which
failed in at least one sample, was removed from the entire
dataset. All probe sequences were mapped to the human
genome (hg19) using BOWTIE2 [117] to identify potential
hybridisation issues. 33,457 probes were identified as
aligning greater than once and these were removed from
the entire dataset. In addition, as our sample cohort was
female, Y chromosome probes were removed from the
dataset. Due to the paired nature of the samples we chose
to retain probes annotated to contain SNPs. Methylation
is expressed as a beta value, which is calculated as the in-
tensity of the methylated channel divided by total intensity
((methylated + unmethylated) + 100). Beta-values range
between 0 (unmethylated) and 1 (completely methylated)
and can be interpreted broadly as the percentage of
methylation for a particular CpG. Methylation for gen-
omic regions was calculated as the mean beta for all
probes located within the region as annotated by Illumina,
TSS200 (TSS - transcription start site), TSS1500, 5′UTR
(UTR - untranslated region), 1st Exon, gene body, 3′UTR
and intergenic. A paired t-test was used to test for statis-
tical difference between the means within each tissue in-
dependently (subcutaneous adipose and omentum) before
and after weight loss. Global methylation profiling of 15
different normal tissue samples (adipose, bladder, blood,
brain, breast, bone, eye, heart, kidney, liver, lung, prostate,
skin, stomach, tongue) used publically available datasets
catalogued by the R package Marmal-aid [118].
Mean Δbeta was calculated for a given CpG site before
weight loss (at gastric bypass) compared to after weight
loss (at second operation). Throughout the manuscript
mean Δbeta is referred to as Δbeta. A positive Δbeta in-
dicates relative hypermethylation before weight loss, and
a negative Δbeta relative hypomethylation. Total Δbeta
was distributed normally for both subcutaneous adipose
and omentum (data not shown). Given the paired nature
of the samples a paired samples t-test was used to test
for significance. Corrections for multiple testing were
made using a Bonferroni adjustment for all sites passing
quality filtering (as above) [47]. All Δbeta values and the
related differentially methylated CpG sites mentioned in
the text have passed Bonferroni correction unless stated
otherwise. Divisive hierarchical clustering was performed
using the Bioconductor Cluster package [119], and the
diana algorithm. Probes were annotated using Illumi-
na450K Manifest information. The Illumina 450 K data
has been deposited in the EBI ArrayExpress database
(E-MTAB-3052).
Identification of DMRs was performed using the probe
lasso method implemented in the R package ChAMP
[48]. This method uses a feature based dynamic window
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genomic feature annotation (probe distribution) to iden-
tify regions of differential methylation between two
groups, in this case before and after gastric bypass and
weight loss. We set a lasso radius of 2,000 bases, the
number of minimum significant probes in the lasso was
three, and the minimum DMR separation was 1,000
bases. Individual probes had to show an adjusted P value
of 0.5 (Benjamini-Hochberg) to be incorporated in to
the analysis. Reported DMRs passed a statistical thresh-
old of P = 0.05).
Pathways enrichment
Enrichment analysis was performed using the WebGes-
talt (WEB-based Gene SeT AnaLysis) Toolkit [120],
[121]. IDs were uploaded and analysis performed against
the human reference genome using a Bonferroni multiple
test adjustment threshold of P <0.05.
QRTPCR
The mean expression (Ct) for 18 s and PPIA combined
was used to normalise the expression of each target gene
(ΔCt). Differential expression before and after gastric by-
pass and weight loss was assessed using a paired t-test.
Fold change in expression between the two time points
(before/after weight loss) was calculated using 2-ΔΔCt.
Additional files
Additional file 1: Global methylation profile of subcutaneous
abdominal adipose and omentum (as Figure 1) alongside 15
different healthy tissues. Mean methylation was calculated across all
probes within each gene region (TSS200, TSS1500, 5′UTR, 1st exon, gene
body, 3′UTR, intergenic) annotated as the Illumina 450 K manifest for 15
tissues (adipose, bladder, blood, brain, breast, bone, eye, heart, kidney,
liver, lung, prostate, skin, stomach, tongue). Mean beta is plotted on the
Y axis, and errors bars denote +/− standard deviation. * Significant
difference between average DNA methylation before and after weight
loss, Bonferroni adjusted P <0.05. Publically available data for healthy
tissues was obtained through catalogues provided by the R package
Marmal-aid.
Additional file 2: Annotated data for the 3,601 differentially
methylated CpG sites passing Bonferroni correction in the analysis
of subcutaneous adipose before and after weight loss. Illumina
probe ID, probe type, gene name and accession number (as Illumina 450 K
manifest) are shown along with methylation statistics; mean_beta_before
and mean_beta_after present mean beta values before and after weight
loss, respectively.
Additional file 3: List of DMRs mapping to 162 annotated loci
identified in subcutaneous adipose tissue. Location, size, P value, and
basic annotation are given for each DMR.
Additional file 4: Correlations between changes in DNA
methylation and clinical trait in subcutaneous adipose. Data for
probes mapping to annotated genes which showed a Pearson’s correlation
between Δmethylation and Δclinical trait of absolute R >0.75 and P <0.05
(Benjamini Hochberg adjusted) for at least one trait are shown.
Additional file 5: Correlations for the comparison of 450 K array
data with pyrosequence analysis for 15 CpG sites in the
subcutaneous adipose samples. Illumina 450 K beta values are plotted(Y axis) against percent methylation using pyrosequencing (X axis). R2
and P values are shown.
Additional file 6: DNA methylation data obtained from the
pyrosequence analysis of subcutaneous adipose in 18 women and
nine men before and after weight loss. Statistics for methylation before
and after weight loss and gastric bypass (mean_methylation_before,
mean_methylation_after) are presented. A paired t-test was performed to
test for a significant difference in methylation before and after weight loss.
CpG sites interrogated (CpG(pyro)) are represented as, for instance,
‘CpGd122’ indicating their location in relation to all other CpGs either ‘u’
upstream or ‘d’ downstream from the transcription start site (TSS) (for example,
CpGd122 is CpG number 122 downstream of the TSS). Chromosomal
locations and Illumina probe IDs are shown.
Additional file 7: DNA methylation data obtained from the
pyrosequence analysis of omentum in 17 women and five men before
and after weight loss. Statistics for methylation before and after weight loss
and gastric bypass (mean_methylation_before, mean_methylation_after) are
presented. A paired t-test was performed to test for a significant difference in
methylation before and after weight loss. CpG sites interrogated (CpG(pyro))
are represented as, for instance, ‘CpGd122’ indicating their location in relation
to all other CpGs either ‘u’ upstream or ‘d’ downstream from the transcription
start site (TSS) (for example, CpGd122 is CpG number 122 downstream of the
TSS). Chromosomal locations are also presented as are Illumina probe IDs.
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